Identifying novel synthetic lethal targets with CRISPR-Cas9



November 11, 2016

  • Share
  • Jon Moore, CSO at Horizon Discovery talks CRISPR-Cas9 and his experiences with technically demanding whole genome negative-selection screens.

    Drug DiscoveryGenomics

    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.